Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic Arthritis

In patients with psoriatic arthritis (PsA), what is the prevalence and infection risk associated with combination targeted therapy (CTT)?In this retrospective cohort study that included 542 CTT patients among 82 399 individuals identified with PsA, the most common CTT was a tumor necrosis factor–α inhibitor and apremilast. There was no significant difference in the risk of serious or opportunistic infection in patients receiving CTT compared with standard therapy.The study results suggest that CTT has a risk of infection similar to standard therapy in adult patients with PsA, but these findings should be further confirmed by larger studies.

Corresponding Author: Joseph F. Merola, MD, MMSc, Department of Dermatology, UT Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75235 (joseph.merola@utsouthwestern.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.